Tim Brake
2
All posts from Tim Brake
Tim Brake in Gainers & Losers,

Lpath (NASDAQ:LPTN) was the recipient of a large decrease in short interest in the month of September.

Lpath (NASDAQ:LPTN) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 633,227 shares, a decrease of 53.9% from the August 31st total of 1,372,461 shares, AnalystRatingsNetwork.com reports. Currently, 2.6% of the company’s stock are short sold. Based on an average daily volume of 451,944 shares, the short-interest ratio is presently 1.4 days.

Lpath, Inc. (NASDAQ:LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that the first cohort of six subjects has been dosed in the Phase 1 clinical trial with LpathomabTM. The double-blind, placebo-controlled, single ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Lpathomab in healthy volunteers. The trial also aims to establish a maximum tolerated dose for future clinical studies in patients with neuropathic pain.

Such a long squeeze. $11.8m cash, zero immediate debt, 28m float. .86c book value? Need some fire..soon